| Author | Title | Summary |
| Shizuta et al., Clin Res Cardiol (2011) |
Prognostic Utility of T-Wave Alternans in a Real-World Population of Patients with Left Ventricular Dysfunction: The PREVENT-SCD Study |
"The event-free rate for severe ventricular tachyarrhythmic events in TWA-negative patients was excellent, 100% at 1 year, 98.6% at 2 years, and 97.0% at 3 years." |
| Merchant et al., Heart Rhythm (2011) |
Clinical Utility of Microvolt T-wave Alternans Testing in Identifying Patients at High or Low Risk of Sudden Cardiac Death (abstract) |
“In patients without ICDs, MTWA testing is a powerful predictor of SCD. Among patients with LVEF ≤ 35%, a negative MTWA test is associated with a low annual risk for SCD. Conversely, among patients with LVEF > 35%, a positive MTWA test identifies patients with a significantly heightened SCD risk.” |
| Hohnloser et al., Heart Rhythm (2009) |
Evidence Regarding Clinical Use of Microvolt T-wave Alternans |
“This study found that MTWA testing using the spectral analytic method provides an accurate means of predicting [ventricular tachyarrhythmic events] in primary prevention patients without implanted ICDs; in particular, the event rate is very low among such patients with a negative MTWA test.” |
| Costantini et al., JACC (2009) |
The ABCD (Alternans Before Cardioverter Defibrillator) Trial: Strategies Using T-Wave Alternans to Improve Efficiency of Sudden Cardiac Death Prevention |
“The ABCD study is the first trial to use MTWA to guide prophylactic ICD insertion. Risk stratification strategies using noninvasive MTWA versus invasive EPS are comparable at 1 year and complementary when applied in combination. Strategies employing MTWA, EPS, or both might identify subsets of patients least likely to benefit from ICD insertion.” |
| Salerno-Uriarte et al., JACC (2007) |
Prognostic Value of T-Wave Alternans in Patients With Heart Failure Due to Nonischemic Cardiomyopathy: Results of the ALPHA Study |
“Among NYHA functional class II/III nonischemic cardiomyopathy patients, an abnormal TWA test is associated with a 4-fold higher risk of cardiac death and life-threatening arrhythmias.” |
| Bloomfield et al., JACC (2006) |
Microvolt T-Wave Alternans and the Risk of Death or Sustained Ventricular Arrhythmias in Patients With Left Ventricular Dysfunction |
“Among patients with heart disease and LVEF ≤ 0.40, MTWA can identify not only a high-risk group, but also a low-risk group unlikely to benefit from ICD prophylaxis.” |
| Chow et al., JACC (2006) |
Prognostic utility of Microvolt T-wave Alternans in Risk Stratification of Patients with Ischemic Cardiomyopathy |
“Microvolt T-wave alternans is a strong and independent predictor of all-cause and arrhythmic mortality in patients with ischemic cardiomyopathy.” |
| Ikeda et al., JACC (2006) |
Predictive Value Of Microvolt T-Wave Alternans for Sudden Cardiac Death in Patients With Preserved Cardiac Function After Acute Myocardial Infarction: Results of a Collaborative Cohort Study |
“In patients with preserved cardiac function, the incidence of indeterminate results of microvolt TWA is low, and a positive test result is associated with arrhythmic events.” |